|
1
|
Ma H, Yuan L, Li W, Xu K and Yang L: The
lncRNA H19/miR-193a-3p axis modifies the radio-resistance and
chemotherapeutic tolerance of hepatocellular carcinoma cells by
targeting PSEN1. J Cell Biochem. 119:8325–8335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Merion RM: Current status and future of
liver transplantation. Semin Liver Dis. 30:411–421. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen G, Li X, He G, Yu Z, Luo J, He J and
Huang Z: Low expression of GNAI3 predicts poor prognosis in
patients with HCC. Int J Clin Exp Med. 8:21482–21486.
2015.PubMed/NCBI
|
|
4
|
Pelus LM and Fukuda S: Peripheral blood
stem cell mobilization: The CXCR2 ligand GRObeta rapidly mobilizes
hematopoietic stem cells with enhanced engraftment properties. Exp
Hematol. 34:1010–1020. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song X, Wang Z, Jin Y, Wang Y and Duan W:
Loss of miR-532-5p in vitro promotes cell proliferation and
metastasis by influencing CXCL2 expression in HCC. Am J Transl Res.
7:2254–2261. 2015.PubMed/NCBI
|
|
6
|
Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang
B, Li BS and Yang SM: The emergence of long non-coding RNAs in the
tumorigenesis of hepatocellular carcinoma. Cancer Lett.
360:119–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qu Z, Yuan CH, Yin CQ, Guan Q, Chen H and
Wang FB: Meta-analysis of the prognostic value of abnormally
expressed lncRNAs in hepatocellular carcinoma. Onco Targets Ther.
9:5143–5152. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun J, Wei X and Xu L: Upregulation of
lncRNA Sox2ot indicates a poor prognosis for patients with
hepatocellular carcinoma and promotes cell invasion. Oncol Lett.
16:1189–1195. 2018.PubMed/NCBI
|
|
9
|
Chang L, Li C, Lan T, Wu L, Yuan Y, Liu Q
and Liu Z: Decreased expression of long non-coding RNA GAS5
indicates a poor prognosis and promotes cell proliferation and
invasion in hepatocellular carcinoma by regulating vimentin. Mol
Med Rep. 13:1541–1550. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang F, Xie C, Zhao W, Deng Z, Yang H and
Fang Q: Long non-coding RNA CARLo-5 expression is associated with
disease progression and predicts outcome in hepatocellular
carcinoma patients. Clin Exp Med. 17:33–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao J, Greene CM, Gray SG and Lawless MW:
Long noncoding RNAs in liver cancer: What we know in, 2014. Expert
Opin Ther Targets. 18:1207–1218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu W, Qiao Y, Tang X, Ma L, Wang Y, Zhang
X, Weng W, Pan Q, Yu Y, Sun F and Wang J: Tumor suppressor long
non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to
inhibit FoxA1 in liver cancer cells. Cell Signal. 26:2961–2968.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan TH, Yang H, Jiang JH, Lu SW, Peng CX,
Que HX, Lu WL and Mao JF: Prognostic significance of long
non-coding RNA PCAT-1 expression in human hepatocellular carcinoma.
Int J Clin Exp Pathol. 8:4126–4131. 2015.PubMed/NCBI
|
|
14
|
Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z,
Deng X, Chen H, Shen B, Peng C, et al: Amplification of long
noncoding RNA ZFAS1 promotes metastasis in hepatocellular
carcinoma. Cancer Res. 75:3181–3191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sonohara F, Inokawa Y, Hayashi M, Yamada
S, Sugimoto H, Fujii T, Kodera Y and Nomoto S: Prognostic value of
long non-coding RNA HULC and MALAT1 following the curative
resection of hepatocellular carcinoma. Sci Rep. 7:161422017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and poweful approach to
multiple testing. J R Stat Soc: Ser B (Methodol). 57:289–300.
1995.
|
|
18
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
The Gene Ontology Consortium: The gene
ontology resource: 20 years and still GOing strong. Nucleic Acids
Res 47D. D330–D338. 2019.
|
|
20
|
Kanehisa M, Sato Y, Furumichi M, Morishima
K and Tanabe M: New approach for understanding genome variations in
KEGG. Nucleic Acids Res 47D. D590–D595. 2019. View Article : Google Scholar
|
|
21
|
Kanehisa M, Furumichi M, Tanabe M, Sato Y
and Morishima K: KEGG: New perspectives on genomes, pathways,
diseases and drugs. Nucleic Acids Res 45D. D353–D361. 2017.
View Article : Google Scholar
|
|
22
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin B, Wang W, Du G, Huang GZ, Han LT,
Tang ZY, Fan DG, Li J and Zhang SZ: Identifying hub genes and
dysregulated pathways in hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 19:592–601. 2015.PubMed/NCBI
|
|
24
|
Dai M, Chen S, Wei X, Zhu X, Lan F, Dai S
and Qin X: Diagnosis, prognosis and bioinformatics analysis of
lncRNAs in hepatocellular carcinoma. Oncotarget. 8:95799–95809.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Antonosante A, d'Angelo M, Castelli V,
Catanesi M, Iannotta D, Giordano A, Ippoliti R, Benedetti E and
Cimini A: The involvement of PPARs in the peculiar energetic
metabolism of tumor cells. Int J Mol Sci. 19(pii): E19072018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ricci M, Miola M, Multari C, Borroni E,
Canuto RA, Congiusta N, Vernè E, Follenzi A and Muzio G: PPARs are
mediators of anti-cancer properties of superparamagnetic iron oxide
nanoparticles (SPIONs) functionalized with conjugated linoleic
acid. Chem Biol Interact. 292:9–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sanchez DJ, Steger DJ, Skuli N, Bansal A
and Simon MC: PPARγ is dispensable for clear cell renal cell
carcinoma progression. Mol Metab. 14:139–149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Q, Peng YS, Chen PJ, Wang ML, Cao C,
Xiong H, Zhang J, Chen MH, Peng XB and Zeng K: Peroxisome
proliferator-activated receptor-γ agonist-mediated inhibition of
cell growth is independent of apoptosis in human epidermoid
carcinoma A431 cells. Oncol Lett. 15:6578–6584. 2018.PubMed/NCBI
|
|
29
|
Xiao YB, Cai SH, Liu LL, Yang X and Yun
JP: Decreased expression of peroxisome proliferator-activated
receptor alpha indicates unfavorable outcomes in hepatocellular
carcinoma. Cancer Manag Res. 10:1781–1789. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Z, Wang Y, Dou C, Sun L, Li Q, Wang L,
Xu Q, Yang W, Liu Q and Tu K: MicroRNA-1468 promotes tumor
progression by activating PPAR-γ-mediated AKT signaling in human
hepatocellular carcinoma. J Exp Clin Cancer Res. 37:492018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Phillips CM, Goumidi L, Bertrais S, Field
MR, Cupples LA, Ordovas JM, Defoort C, Lovegrove JA, Drevon CA,
Gibney MJ, et al: Gene-nutrient interactions with dietary fat
modulate the association between genetic variation of the ACSL1
gene and metabolic syndrome. J Lipid Res. 51:1793–1800. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ong KT, Mashek MT, Bu SY, Greenberg AS and
Mashek DG: Adipose triglyceride lipase is a major hepatic lipase
that regulates triacylglycerol turnover and fatty acid signaling
and partitioning. Hepatology. 53:116–126. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cui M, Xiao Z, Wang Y, Zheng M, Song T,
Cai X, Sun B, Ye L and Zhang X: Long noncoding RNA HULC modulates
abnormal lipid metabolism in hepatoma cells through an
miR-9-mediated RXRA signaling pathway. Cancer Res. 75:846–857.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Korobkova EA: Effect of natural
polyphenols on CYP metabolism: Implications for diseases. Chem Res
Toxicol. 28:1359–1390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zanger UM and Schwab M: Cytochrome P450
enzymes in drug metabolism: Regulation of gene expression, enzyme
activities, and impact of genetic variation. Pharmacol Ther.
138:103–141. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou J, Wen Q, Li SF, Zhang YF, Gao N,
Tian X, Fang Y, Gao J, Cui MZ, He XP, et al: Significant change of
cytochrome P450s activities in patients with hepatocellular
carcinoma. Oncotarget. 7:50612–50623. 2016.PubMed/NCBI
|
|
37
|
Gonzalez FJ and Gelboin HV: Role of human
cytochrome P-450s in risk assessment and susceptibility to
environmentally based disease. J Toxicol Environ Health.
40:289–308. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Messina ES, Tyndale RF and Sellers EM: A
major role for CYP2A6 in nicotine C-oxidation by human liver
microsomes. J Pharmacol Exp Ther. 282:1608–1614. 1997.PubMed/NCBI
|
|
39
|
Gullstén H, Agúndez JA, Benítez J, Läärä
E, Ladero JM, Díaz-Rubio M, Fernandez-Salguero P, Gonzalez F,
Rautio A, Pelkonen O and Raunio H: CYP2A6 gene polymorphism and
risk of liver cancer and cirrhosis. Pharmacogenetics. 7:247–250.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nowell S, Sweeney C, Hammons G, Kadlubar
FF and Lang NP: CYP2A6 activity determined by caffeine phenotyping:
Association with colorectal cancer risk. Cancer Epidemiol
Biomarkers Prev. 11:377–383. 2002.PubMed/NCBI
|
|
41
|
Kamataki T, Nunoya K, Sakai Y, Kushida H
and Fujita K: Genetic polymorphism of CYP2A6 in relation to cancer.
Mutat Res. 428:125–130. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cui H, Zhang Y, Zhang Q, Chen W, Zhao H
and Liang J: A comprehensive genome-wide analysis of long noncoding
RNA expression profile in hepatocellular carcinoma. Cancer Med.
6:2932–2941. 2017. View Article : Google Scholar : PubMed/NCBI
|
